(NGSX) (NGSX) Stock Price, News & Analysis

Company Overview

NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pains management therapies to address unmet medical needs. Qutenza is the Company's first commercial product, available in the United States and in certain European countries. Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions and was approved by the food and drugs administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia (PHN). Qutenza is also approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults. The Company's advanced drug candidate is NGX-1998. NGX-1998 is a topical liquid formulation of high concentration capsaicin that the Company is developing to treat neuropathic pain conditions.

Key Stats

• Today's Range: $0.0050 to $0.0050
• 50-Day Range: N/A
• 52-Week Range: $0.0025 to $0.0150
• Volume: N/A
• Average Volume: 70,548 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NGSX
• CIK: 1385830
• Web: www.neurogesx.com
• Phone: +1-650-3583300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A